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Abstract
Background: Duchenne muscular dystrophy (DMD) is an incurable disease, caused by the mutations in the DMD
gene, encoding dystrophin, an actin-binding cytoskeletal protein. Lack of functional dystrophin results in muscle
weakness, degeneration, and as an outcome cardiac and respiratory failure. As there is still no cure for affected
individuals, the pharmacological compounds with the potential to treat or at least attenuate the symptoms of the
disease are under constant evaluation. The pleiotropic agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, known as statins, have been suggested to exert beneficial effects in the mouse model of DMD.
On the other hand, they were also reported to induce skeletal-muscle myopathy. Therefore, we decided to verify
the hypothesis that simvastatin may be considered a potential therapeutic agent in DMD.
Methods: Several methods including functional assessment of muscle function via grip strength measurement,
treadmill test, and single-muscle force estimation, enzymatic assays, histological analysis of muscle damage, gene
expression evaluation, and immunofluorescence staining were conducted to study simvastatin-related alterations in
the mdx mouse model of DMD.
Results: In our study, simvastatin treatment of mdx mice did not result in improved running performance, grip
strength, or specific force of the single muscle. Creatine kinase and lactate dehydrogenase activity, markers of
muscle injury, were also unaffected by simvastatin delivery in mdx mice. Furthermore, no significant changes in
inflammation, fibrosis, and angiogenesis were noted. Despite the decreased percentage of centrally nucleated
myofibers in gastrocnemius muscle after simvastatin delivery, no changes were noticed in other regeneration-
related parameters. Of note, even an increased rate of necrosis was found in simvastatin-treated mdx mice.
Conclusion: In conclusion, our study revealed that simvastatin does not ameliorate DMD pathology.
Keywords: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Simvastatin, DMD, Duchenne muscular
dystrophy, Angiogenesis, mdx
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Background
Duchenne muscular dystrophy (DMD) is a progressive,
severely debilitating, and lethal genetic disease caused by
the mutations in the DMD gene, coding dystrophin, a
427 kDa actin-binding cytoskeletal protein, maintaining
muscle fiber-extracellular matrix integrity and regulating
several cellular pathways including nitric oxide (NO)
production, Ca2+ entry, and the generation of reactive
oxygen species (ROS) [1, 2]. In DMD, progressive
muscle weakness, together with the loss of muscle mass
and function, is a consequence of several pathological
processes namely necrosis, inflammation, fibrosis, and
increased oxidative stress which are results of unbal-
anced regenerative processes (reviewed in [3]). Recent
discoveries and our research underlined also the dysreg-
ulation of angiogenesis as an additional mechanism ac-
companying muscle insufficiency [4–6]. As the disease
progresses, patients suffering from DMD lose the ability
to walk and ultimately die in the 2nd to 3rd decade of
life, due to cardiac or respiratory failure [7, 8].
Taking into account the diversity of the processes
which may affect DMD progression and the constant
need for the development of effective therapeutics, new
factors are suggested to exhibit beneficial effects on this
so far incurable disease. In our previous study, we have
found that lack of heme oxygenase-1 (Hmox1, HO-1), a
heme-degrading enzyme, exerting anti-oxidant and cyto-
protective activities leads to a more severe disease state
through, among others, aggravation of inflammation and
fibrosis [9]. Hmox1 expression may be modulated by the
plethora of compounds, including 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
[10], commonly known as statins, discovered 40 years
ago [11] and used as lipid-lowering drugs for the treat-
ment of hypercholesterolemia and reduction of athero-
sclerosis. Interestingly, in 2015, Whitehead et al. for the
first time showed that simvastatin improves muscle
health, reduces inflammation and oxidative stress, and
increases autophagy in mdx animals [12] and Kim et al.
reported beneficial effects on heart functions [13]. Simi-
larly, Amor et al. suggested simvastatin treatment as a
potential therapeutic agent in DMD due to its role in
the regulation of cholesterol metabolism [14]. However,
other studies performed with simvastatin [15] and rosu-
vastatin [16] did not confirm such favorable properties
in animal models of DMD.
What is relevant, even the devastating role of statins
on muscles has been reported, however, concentrations
required to induce deleterious effects in vitro are far be-
yond the physiological range, being typically greater than
1 μM. Such concentrations are considerably (100–1000
times) higher than those found in vivo in humans [17].
There are also discrepant data about the incidence of
different kinds of myopathy in humans after statin
therapy. Previous studies indicated a high risk of such
adverse effects, e.g., showing that >10% of statin users in
the general population can be affected [18, 19]. Note-
worthy, a recent systematic reviews of clinical trials
found an extremely low risk of adverse muscle symp-
toms in statin takers compared with placebo controls
[20, 21]. Particularly, high risk of myopathy was ob-
served in patients who take 80 mg of simvastatin daily in
comparison to those taking 20 to 40 mg, indicating
exposure-dependent myotoxicity. Additionally, risk and
severity may increase in the specific genetic variants, es-
pecially those affecting blood statin levels (e.g.,
SLCO1B1 encoding the organic anion-transporting poly-
peptide OATP1B1, which has been shown to regulate
the hepatic uptake of statins) or in the presence of co-
medications known to influence statin metabolism (e.g.,
cyclosporine) [22]. Statin-related muscle symptoms also
appear to be exacerbated by other factors, including ex-
ercise [23], older age, and female sex [24]. On the other
hand, Iwere and Hewitt showed, that even in aged pa-
tients (65+ years), the risk of statin-induced myopathy
was comparable to placebo patients [25], which was also
confirmed recently by Zhou et al. [26]. These data impli-
cate that the fear of statin-caused myopathy might be in
many cases overestimated. Notably, the abovementioned
risk factors for statin-induced myopathy are not relevant
to boys with DMD. However, it cannot be excluded that
damaged muscles in DMD patients may be per se a po-
tential risk factor for statin-associated myopathy.
Based on the published, contradictory results in the
field of statin-induced muscle alterations [18–26] and
their ambiguous role in muscular dystrophy [12–16] as
well as our previous expertise in terms of the role of sta-
tins, including the angiogenesis process [27, 28], we
aimed at the evaluation of the effect of simvastatin in
mdx animals. We have found that simvastatin does not
regulate important processes contributing to dystrophy
progressions like fibrosis, inflammation, regeneration,
angiogenesis, and finally, does not improve muscle func-
tionality. Therefore, based on our results, we may con-
clude that simvastatin does not exert beneficial effects in
the mdx model of DMD.
Materials and methods
Cell culture
C2C12 murine myoblast cells were maintained in
DMEM high glucose (4.5 g/l) medium supplemented
with 10% fetal bovine serum (FBS) and antibiotics:
streptomycin (100 μg/ml) and penicillin (100 U/ml)
(Lonza). The cells were kept at standard conditions
(37°C, 5% CO2, 95% humidity). C2C12 myoblasts were
stimulated for 24 h with 0.1 and 1 μM concentrations of
simvastatin (Sigma-Aldrich).
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Animals
Animal experiments were conducted in accordance with
the national and European legislation, after approval by
the 2nd Institutional Animal Care and Use Committee
(IACUC) in Kraków, Poland (approvals numbers: 323/
2018, 301/2019, 79/2021, and 170/2021). All mice used
in the study were 6-week-old WT and mdx male litter-
mates or age-matched mice from generations F2 to F5,
bred on a mixed C57BL/10ScSn and C57BL/6×FVB
background as described by us previously [9], and
housed in specific pathogen-free (SPF) conditions with
water and food available ad libitum. Genotyping of ani-
mals was performed using PCR on the DNA isolated
from the tails. Statin administration was continued for 1
month until the age of 10 weeks.
Simvastatin treatment
An activation procedure was based on the published
protocol [29]. Briefly, 4 mg of simvastatin (Sigma-Al-
drich) was dissolved in 200 μl of ethanol. Then 300 μl of
0.1 N NaOH was added to the solution and subsequently
incubated at 50°C for 2 h. The pH was brought to 7.2 by
HCl, and the concentration of the stock solution was ad-
justed to 2 mg/ml. The stock solution was kept at 4°C.
For 1 month mdx mice received either 10 mg/kg body
weight (BW) simvastatin/day via oral gavage or solvent
(vehicle group). WT animals receiving vehicle were used
as a reference group. The administered dose was chosen
based on the literature data [12].
Simvastatin level estimation and pharmacokinetics
Analyzes of simvastatin and its acid form were per-
formed at the Mass Spectrometry Laboratory at the In-
stitute of Biochemistry and Biophysics Polish Academy
of Science using the liquid chromatography-tandem
mass spectrometry method (LC-MS/MS). Pharmacokin-
etics was assessed after 30 min, 1 h, 2 h, and 4 h after
administration of simvastatin to mdx mice. What is
more, the level of simvastatin and its metabolite was
measured in the plasma and muscles at the end of 1-
month-lasting experiment, 24 h after the last treatment.
Muscle homogenates were prepared in 10% ethanol (1
mg muscle/4 μl homogenate mixture). Simvastatin, sim-
vastatin acid form, and internal standard were isolated
from a biological sample by liquid-liquid extraction
(LLE). Biological samples (plasma, muscle homogenate)
and calibrators were spiked with lovastatin (250 ng/ml
in acetonitrile) (Sigma-Aldrich). Analytes were extracted
with methyl tert-butyl ether (J.T. Baker) and 50 mM am-
monium acetate (J.T. Baker). Finally, samples were
reconstituted in 50% acetonitrile (J.T. Baker) and ana-
lyzed using the Waters Acquity Ultra Performance Li-
quid Chromatograph (Waters) coupled with Waters TQ-
S triple-quadrupole mass spectrometer (Waters). For the
instrument control and data acquisition, Waters Mas-
sLynx software was used whereas data processing was
done with Waters TargetLynx (Waters). Chromato-
graphic separation was performed using a Waters C18
column (1.7 μm, 2.1 mm × 50mm) (Waters). Mobile
phase A was 2-mM ammonium acetate (J.T. Baker) with
0.1% formic acid (v/v) (J.T. Baker) in water, and mobile
phase B was acetonitrile (J.T. Baker). The mass spec-
trometer was operated in multiple-reaction monitoring
(MRM)-positive electrospray ionization (ESI+) mode.
The concentrations of analytes were calculated using
calibration standard mix derived from a series of calibra-
tor samples by spiking standard stock solutions into
water. Calibration curves were generated by comparing a
ratio of the peak area of the analyzed compound to the
peak of the internal standard against known analyte con-
centrations. The limits of quantification were 0.1 ng/ml
and 0.5 ng/ml for simvastatin and acid form,
respectively.
Grip strength assay
Forelimb grip strength was assessed by the investigator
blind to the mice’s genotype on day 26 of simvastatin
administration, using a grip strength meter with a tri-
angular pull bar (Ugo Basile) as described earlier [30,
31]. The measurements were repeated 5 times with a 1-
min break in between. Following the instruction de-
scribed in the TREAT-NMD SOP (https://treat-nmd.
org/wp-content/uploads/2016/08/MDX-DMD_M.2.2.
001.pdf), results were calculated as an average from 3
highest measurements and expressed as absolute values
(N), or normalized to body weight (N/kg BW).
Treadmill test
The treadmill exhaustion test was performed on day 29,
using the Exer-3/6 (Columbus Instruments) at 15°
downhill by the investigator blind to the mice’s geno-
type. We employed the protocol described previously [9]
with modification. Briefly, after 3 daily acclimation ses-
sions of 15 min at 8 m/min, 10-week-old male mice
were subjected to an exhaustion treadmill test. Mice
were warmed up at 5 m/min for 5 min, and then, they
ran on the treadmill at 5 m/min for 2 min, 7 m/min for
2 min, 8 m/min for 2 min, 10 m/min for 5 min, and 12
m/min for 15 min. Afterward, the speed was increased
by 1 m/min to a final speed of 20 m/min. The endpoint
for each mouse was defined by the inability of the ani-
mal to remain on the treadmill after 10 stimulations
with gentle touching.
Muscle contractile properties
The specific maximum force of the tibialis anterior
muscle was assessed on day 30 (1 day after the last dose)
using Aurora 1300A: 3-in-1 Whole Animal System
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(Aurora Scientific) by measuring in situ muscle contrac-
tion in response to nerve stimulation with the trains of
stimuli with increasing frequencies from 50 to 150 Hz.
The determined maximal force was further normalized
to the muscle weight. In fatigue protocol, we evaluated
the decrease in the force of a muscle over time due to
continuous stimulation of 50 Hz for 30 s. For analysis,
we determined the time after which a drop in muscle
force by 50% of basal value was obtained. Analysis was
performed with the researcher blind to the genotype of
the mice.
Blood cell count
The blood was collected directly from the vena cava to
the EDTA-coated tubes and the total number of white
blood cells (WBC) and the percentage of granulocytes,
monocytes, and lymphocytes among WBC was analyzed
using scil Vet abc (Horiba ABX).
Histological and immunofluorescent analysis of the
muscles
For histological assessment muscles were collected and
pre-treated with OCT medium (Leica) for few minutes
directly after collection. Afterward, they were transferred
to new, OCT-containing tubes, frozen in liquid
nitrogen-cooled isopentane, and stored at −80°C. Then,
10-μm-thick sections were cut on a cryotome (Leica),
placed on the previously coated with poly-L-lysine slides,
air-dried for at least 2 h, and kept at −20°C for further
analyses. Hematoxylin and eosin (H&E) staining and
Masson’s trichrome were performed on the 4% buffered
formalin-fixed (pH 7.4) frozen sections. For H&E, tissue
sections were incubated in Mayer’s hematoxylin (Sigma-
Aldrich) for 12 min, rinsed with tap water (15 min), and
stained for 1.5 min in 0.1% eosin solution (96% EtOH
and distilled water, 7:3) (Sigma-Aldrich). After the stain-
ing, the sections were incubated in increasing concentra-
tions (70%, 96% (×2), 99.8% (×2)) of aqueous EtOH
(POCH), then 2 times in xylene (Sigma-Aldrich) and
sealed in Histofluid medium (Chemilab). Masson’s tri-
chrome (Trichrome Stain (Masson) Kit, Sigma-Aldrich)
was performed following the manufacturer’s protocol.
After the staining, the sections were incubated in in-
creasing concentrations (70%, 96% (×2), 99.8% (×2)) of
aqueous EtOH, then 2 times in xylene and sealed in His-
tofluid medium (Chemilab). Analyses were conducted
according to our previous studies [4, 9, 32] after taking
pictures of the whole tissues. The assessment of inflam-
mation and fibrosis extent was conducted using arbitrary
units, respectively: 0—no signs of inflammation/collagen
deposition; 1—any sign of leukocyte infiltration and
myofiber swelling/collagen deposition; 2—visible inflam-
mation, myofiber swelling, and rhabdomyolysis/collagen
deposition; 3—signs of inflammation, myofiber swelling,
and rhabdomyolysis which take around half of a field of
view/collagen deposition takes up around half of the
field of view; and 4—a substantial part of the muscle in
the field of view is infiltrated and degenerated/collagen
deposition takes the substantial part of the field of view.
The analysis of centrally nucleated fibers (CNF) indicat-
ing the level of regeneration was performed based on
H&E staining; 10–15 pictures/tissue section were ran-
domly taken and the percentage of CNF among all fibers
was calculated.
Immunofluorescent staining of CD31/α-SMA-positive
vessels was performed as described by us previously with
slight modifications [33]. Primary antibodies: rat anti-
mouse CD31 (BD Pharmingen, 550274) and rabbit anti-
human α-SMA (Abcam, ab5694) were used followed by
the incubation with secondary antibodies: goat anti-rat
Alexa Fluor 488 (for detection of α-SMA) and goat anti-
rabbit Alexa Fluor 568 (for detection of CD31). Pictures
of the whole tissue were taken, and CD31/α-SMA-posi-
tive vessels were analyzed quantitatively per muscle area.
The results were presented as a number of vessels per
area. Pax7/laminin co-staining was performed as de-
scribed before [5, 31]. Necrosis was assessed by the im-
munofluorescent staining of the IgG/IgM/IgA (goat anti-
mouse IgG, IgM, IgA Alexa Fluor 488 antibody, Thermo
Fisher Scientific) with laminin α2 (rabbit anti-mouse
antibody, Abcam, ab11576; secondary antibody: goat
anti-rabbit Alexa Fluor 568) and showed as a percentage
of necrotic fibers in the stained muscle. Evaluation of
the muscle cross-sectional area (CSA) and the mean
fiber area was determined by semi-automatic muscle
analysis using segmentation of histology (SMASH) [34]
based on immunofluorescent staining of laminin.
The stainings were visualized under Nikon Eclipse Ti
fluorescent microscope. All histological assessments were
analyzed by the investigator blind to the mice group using
ImageJ software. If necessary, the brightness and/or con-
trast were adjusted to all of the pictures equally.
Determination of serum CK and LDH concentrations
To estimate the activity of CK and LDH diagnostic
Liquick Cor-CK and Liquick Cor-LDH kits were used,
respectively, according to the manufacturer protocols
(Cormay). The blood was collected from vena cava and
was allowed to clot at room temperature for 30 min and
then centrifuged at 4°C for 10 min at 2000g. The assay
was performed using a clear serum, without the signs of
hemolysis. The absorbance values were then converted
to CK and LDH (U/l).
RNA isolation, reverse transcription (RT), and quantitative
real-time PCR (qRT-PCR)
The collected muscles were protected in RNAlater
(Sigma-Aldrich), snap-frozen in liquid nitrogen, and
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stored at −80°C for downstream analyses. RNA was iso-
lated as in our previous study [9] using the
Chomczynski-Sacchi method [35]. Its quality and con-
centration were determined by the NanoDrop Spectro-
photometer (Thermo Fisher Scientific). qRT-PCR was
performed as described previously [9] using StepOne
Plus Real-Time PCR (Applied Biosystems - Thermo
Fisher Scientific) and SYBR Green PCR Master Mix
(Sigma-Aldrich), specific primers (listed in Table 1), and
cDNA obtained in the RT reaction with recombinant
M-MuLV reverse transcriptase (Thermo Fisher Scien-
tific). Eef2 was used as a housekeeping gene. The expres-
sion of miR-1, miR-133a-3p, and miR-206 was
normalized to the constitutive SNORD68 gene (LNA
miRCURY RT-PCR Kit and miRCURY LNATM miRNA
PCR Assay). Relative quantification of gene expression
was calculated based on the comparative cycle threshold
(Ct) method (according to the 2
-ΔCt formula where ΔCt
= Ct gene of interest – Ct Eef2/SNORD68) and presented as the
relative expression in comparison to vehicle-treated WT
animals.
Enzyme-linked immunosorbent assay (ELISA)
The fragments of the muscles were snap-frozen in liquid
nitrogen, homogenized in 1% Triton X-100 in PBS using
TissueLyser (QIAGEN), and centrifuged (7000g, 10 min,
4°C). The protein lysates were collected, and the total
protein concentration was measured by bicinchoninic
acid (BCA, Sigma-Aldrich) assay. One hundred
micrograms of protein lysate was used to determine the
level of vascular endothelial growth factor (VEGF), fibro-
blast growth factor-2 (FGF2), endoglin (CD105), and
stromal cell-derived factor-1 (SDF-1) according to the
vendor’s instructions (R&D Systems). To assess the level
of osteopontin (OPN), 750 times-diluted mouse serum
was subjected to the test and the concentration was
quantified based on the absorbance values according to
the manufacturer’s protocol (R&D Systems).
Statistical analyses
Data are presented as mean ± SEM. Differences between
groups were tested for statistical significance using the
one-way ANOVA followed by Tukey’s post hoc test; p <
0.05 was considered significant. The outliers were identi-
fied based on Grubb’s test.
Results
Simvastatin treatment does not influence CK and LDH
activities in mdx mice
Administration of simvastatin for 1 month in a dose of
10 mg/kg BW/day by oral gavage did not result in the
change in BW of the animals (Fig. 1A). Moreover, the
blood cell analysis did not reveal any detrimental effect
of statin treatment with regard to WBC (Fig. 1B), granu-
locytes (Fig. 1C), monocytes (Fig. 1D), and lymphocytes
(Fig. 1E), measured at the end of the experiment.
One of the hallmarks of DMD is the elevated level of
serum markers of muscle damage [36]. Accordingly, the
activity of CK (Fig. 1F) and LDH (Fig. 1G) was potently
increased in the dystrophic animals, with no effect upon
drug administration.
Simvastatin treatment fails to improve the exercise
capacity, forelimb grip strength, and contractile
properties of the mdx mice
To assess the functional effect of statin treatment, we
carried out three types of tests. The treadmill exhaustion
experiment did not show any difference in the running
capacity of simvastatin-treated mdx mice when com-
pared to the vehicle-treated mice (Fig. 2A). Similarly,
muscle function in dystrophic animals after simvastatin
administration was not altered in the forelimb grip
strength test (Fig. 2B, C). Furthermore, when tibialis an-
terior contractility was measured using the Aurora sys-
tem, no apparent improvement was noticed upon
treatment, both with regard to the maximal force meas-
urement and in fatigue analysis (Fig. 2D, E), respectively.
Simvastatin treatment does not affect inflammation in
the dystrophic muscles
A dramatic exacerbation in inflammatory cell infiltration
was observed both in the gastrocnemius as well as in the
diaphragm of dystrophic animals; however, H&E staining
Table 1 The sequences of primers used for the determination
of gene expression by qRT-PCR
Gene Sequence 5’-3’
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did not reveal any effect of simvastatin on inflammation,
regardless of the type of the analyzed muscle (Fig. 3A,
Supplementary Fig. 1A). Accordingly, heme oxygenase-1
(Hmox1), a marker of inflammation and oxidative stress
augmented in dystrophic animals, was affected by the
treatment neither in gastrocnemius (Fig. 3B) nor the dia-
phragm (Supplementary Fig. 1B). The muscle necrosis,
as assessed by the immunofluorescent staining of the
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Fig. 1 Simvastatin treatment does not affect WBC abundance and CK and LDH activity. A Changes in the body weight (BW) over the time of
simvastatin treatment; n=10–15/group. Results presented as a percentage of initial weight (mean ± SEM). B Unchanged number of white blood
cells (WBC) in the peripheral blood; n=5–6/group. Increased percentage of C granulocytes and D monocytes in dystrophic animals compared to
the WT mice without the effect of simvastatin. E Diminished percentage of lymphocytes in dystrophic animals compared to the WT mice without
simvastatin-related changes. F Augmented serum activity of CK in mdx animals with no effect of the drug in simvastatin-treated dystrophic mice;
n=5–6/group. G Increased serum LDH activity in mdx mice without simvastatin-related alterations; n=5–6/group. Results shown as a mean ± SEM;
**p < 0.01 and ****p < 0.0001































































Fig. 2 The exercise capacity, grip strength, and muscle contractility are not altered upon simvastatin treatment. A Downhill running treadmill test
presented as the total distance run by mice during the test n=5–8/group, mean ± SEM. B Forelimb grip strength analysis is shown as the
absolute values or C normalized to body weight (N/kg BW); n=5–8/group, mean ± SEM. D Specific maximum force and E fatigue analysis of the
tibialis anterior muscle; in situ muscle contractile measurements using the Aurora system; n=4–7; mean ± SEM; *p < 0.05, **p < 0.01
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Fig. 3 (See legend on next page.)
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IgG/IgM/IgA, the membrane-impermeable markers, was
even intensified upon simvastatin administration, as evi-
denced by a higher number of necrotic fibers in the
gastrocnemius muscle of simvastatin-treated mdx mice
(Fig. 3C).
Simvastatin does not reduce fibrosis in dystrophic
animals
In dystrophic muscles, collagen deposition was clearly
visible; however, the simvastatin treatment did not at-
tenuate fibrosis as shown by semi-quantitative analysis
of trichrome staining both in gastrocnemius (Fig. 3D)
and in diaphragm (Supplementary Fig. 1C) muscles. Of
note, the mRNA (Spp1) and protein level of OPN, one
of the markers of fibrosis, elevated in mdx mice, were
not affected by statin treatment (Fig. 3E, F, Supplemen-
tary Fig. 1D). Furthermore, the augmented expression of
other fibrotic factors, including transforming growth
factor-beta 1 (Tgfb1) and matrix metalloproteinase 11
(Mmp11) was unchanged by simvastatin in both ana-
lyzed muscles (Fig. 3G, Supplementary Fig. 1E). Al-
though there was a significant decrease in collagen type
I alpha 1 chain (Col1a1) in the gastrocnemius (Fig. 3G),
no such effect was found in the diaphragm (Supplemen-
tary Fig. 1E).
Simvastatin treatment does not influence muscle
regeneration
The size of the fibers appeared to be smaller in vehicle-
treated mdx mice when compared to the WT counter-
parts (Fig. 4A, B), whereas the mean fiber size was in-
creased in the gastrocnemius muscle of dystrophic
animals upon simvastatin treatment (Fig. 4A, B). At the
same time, the percentage of CNF was lower when
simvastatin-treated mdx mice were compared to the ve-
hicle group; however, still, it was greatly increased in
comparison to WT animals, in which almost no fibers
with central nuclei have been found (Fig. 4C). On the
contrary, no changes in fiber size, mean fiber size, and
CNF were noticed after statin treatment in the dia-
phragm, although the differences between WT and mdx
animals were still prominent (Supplementary Fig. 1F-H).
Importantly, also the expression of embryonic myosin
heavy chain isoform Myh3, encoding eMyHC especially
relevant in the matter of muscle regeneration [37], des-
pite being increased in the dystrophin-lacking vehicle
group, was unaffected by statin treatment (Fig. 4D). In
addition, the protein level of FGF2, upregulated during
regeneration [38], was not significantly changed in the
gastrocnemius of simvastatin-receiving animals (Fig. 4E).
As microRNAs, especially the so-called myomiRs, play
an important role in muscle regeneration [39], we de-
cided to check the expression of the three miRNAs:
miR-1, miR-133a-3p, and miR-206. A significant down-
regulation of miR-1 and miR-133-3p, and upregulation
of miR-206 were evident in vehicle-treated mdx animals,
but simvastatin was not able to change their expression
(Fig. 4F). Also, when the number of Pax7-positive satel-
lite cells was estimated in the gastrocnemius muscles, we
observed their prominent elevation in dystrophic ani-
mals treated with the vehicle with no further effect of
simvastatin administration (Fig. 4G).
Simvastatin treatment does not affect angiogenic markers
and vascularization in dystrophic muscles
Recent discoveries underline the role of dysregulation of
angiogenesis in DMD pathology [4, 5, 31, 40]. In our
previous studies, we have found the concentration- and
cell-type dependent effect of statins on VEGF synthesis
and overall angiogenic activity [27, 41, 42]. However, in
the C2C12 mouse, myoblast cell line simvastatin at the
physiologically relevant concentrations (0.1–1 μM) did
not affect Vegfa (Supplementary Fig. 3). In vivo, simva-
statin treatment of dystrophic animals did not cause any
alterations in the expression of already decreased in
most cases angiogenic genes, such as Vegfa, kinase insert
domain receptor (Kdr), angiopoietin-1 (Ang1), and C–
X–C motif chemokine 12 (Cxcl12), also known as gene
coding stromal cell-derived factor 1 (SDF-1) (Fig. 5A).
Importantly, VEGF (Fig. 5B), as well as SDF-1 (Fig. 5C)
and endoglin (CD105) (Fig. 5D) protein levels, were also
unaffected. Furthermore, no effect of statin treatment on
the analyzed factors was observed in the diaphragm,
both on mRNA and protein level (Supplementary Fig.
(See figure on previous page.)
Fig. 3 Simvastatin treatment does not attenuate inflammation and fibrosis in gastrocnemius of mdx mice. A Representative pictures of
hematoxylin and eosin (H&E) staining of the gastrocnemius muscle with semi-quantitative analysis of inflammation; scale bar: 100 μm; mean ±
SEM; n=5–6/group. B Unaffected by simvastatin treatment expression of Hmox1 gene in gastrocnemius, presented as a mean ± SEM; n=10–13;
qRT-PCR. C Necrosis assessment using immunofluorescent staining of IgM/IgG/IgA binding (green) with laminin (red) and its calculation
presented as a mean ± SEM; n=6–13/group; scale bar: 100 μm. D Representative photos of Masson’s trichrome staining with semi-quantitative
analysis of collagen deposition showing no changes in the extent of fibrosis in gastrocnemius of simvastatin-treated animals; scale bar: 100 μm;
n=5/group. E Unaffected by simvastatin treatment expression of Spp1 gene in gastrocnemius, presented as a mean ± SEM; n=10–14; qRT-PCR. F
The protein level of serum marker of fibrosis, OPN, n=10–13/group, mean ± SEM; ELISA. G Unaltered by the treatment expression of fibrotic
markers: Tgfb1 and Mmp11, in gastrocnemius of mdx mice and a significant decrease in Col1a1 mRNA; n=12–14/group, WT level marked with the
dotted line; qRT-PCR. Data are presented as mean ± SEM; *for mdx vehicle vs. WT and # for mdx simvastatin vs. mdx vehicle comparison; *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and #p < 0.05








































































































































































































Fig. 4 (See legend on next page.)
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2A-D). Additionally, when the number of CD31+/α-
SMA+ vessels was evaluated in gastrocnemius muscle,
no differences were noted after statin delivery (Fig. 5E).
Interestingly, a significant rise in the number of CD31+/
α-SMA+ vessels was observed in the diaphragm, showing
differences between various muscles (Supplementary Fig.
2E).
The level of simvastatin and its active form declines
rapidly after administration
In order to determine, whether the lack of simvastatin
effect in our studies could be explained by low plasma
levels and insufficient muscle distribution of the drug,
we performed the pharmacokinetic analysis of the sim-
vastatin and its active, acid form. Our results showed a
detectable concentration of both simvastatin and its me-
tabolite in plasma (Fig. 6A, B) and in the diaphragm
(Fig. 6C, D) in all-time points (30 min–4 h). Interest-
ingly, in gastrocnemius muscle, we were not able to de-
tect simvastatin, whereas the concentration of the active
metabolite was considerably lower than in the dia-
phragm (Fig. 6E). Importantly, the level of active form of
simvastatin in the plasma and diaphragm was consider-
ably higher than the corresponding level of simvastatin,
what was expected as the activation of simvastatin was
performed before in vivo administration via oral gavage.
Nevertheless, in all tested samples, the level of both
forms declines rapidly over time. In addition, when sim-
vastatin and simvastatin acid form concentrations were
assessed 24 h after the last dose of monthly administra-
tion, their level was undetectable in all samples.
Discussion
Despite many years of intensive and profound studies,
DMD remains an incurable disease. The newest, most
promising therapies, using the latest advances in genetic
modification, namely CRISPR/Cas9 technology, are still
far from clinical introduction and acceptance. Thus, glu-
cocorticoids constantly serve as a gold standard therapy
for patients suffering from DMD. Unfortunately, except
for undoubtful beneficial impact on DMD pathology,
their daily administration was shown to exert many side
effects leading to, among others, osteoporosis, diabetes,
or muscle atrophy [43]. As there is a constant need to
investigate novel strategies, which could at least attenu-
ate the severity of the disease, many researchers focus
not only on new drug discoveries but also on the repur-
posing of the already existing ones.
HMG-CoA reductase inhibitors, commonly known as
statins, seem to be the perfect choice for such investiga-
tion. Despite the still ongoing discussion regarding
statin-induced myopathy, myositis, and rhabdomyolysis
[17, 19, 23, 44] recent studies describe that the benefits
of the treatment, outweigh the possible risks which, of
note, are usually not relevant to DMD boys [21, 26]. Sev-
eral studies demonstrated the positive effects of statins
on overall skeletal muscle health, including their anti-
inflammatory and anti-fibrotic properties [45, 46].
Whitehead et al. already showed in 2015 the protective
influence of simvastatin in dystrophic animals [12], and
similarly, promising results were published this year by
Amor et al. [14]. On the other hand, the 2020 publica-
tion by Verhaart et al. described the lack of the effect of
such treatment [15]. Also, when different statins were
investigated by other groups, the results were inconclu-
sive. Pravastatin, another FDA-approved cholesterol-
lowering drug, was proposed to upregulate the expres-
sion of utrophin A [47], an autosomal homolog of dys-
trophin, compensating for its loss in DMD muscles [48].
On the other hand, Finkler et al. demonstrated no bene-
ficial effects of rosuvastatin and even a visible accretion
of inflammation was remarked upon treatment [16].
In our study, simvastatin was not able to alleviate dys-
trophic muscle pathology and even a significantly higher
percentage of necrotic fibers was detected in dystrophic
animals after drug delivery, which might suggest deteri-
oration of the muscles’ condition. Nevertheless, no other
tested parameters seem to confirm aggravation of the
disease as no elevation in CK level, strongly associated
with statin-induced myopathy [44], was observed after 1
month of simvastatin administration. Moreover, no sig-
nificant or alarming systemic changes were observed in
regards to the total WBC or distinguished subpopula-
tion, e.g., granulocytes, lymphocytes, and monocytes,
when simvastatin-treated animals were compared to the
mdx vehicle group at the end of the experiment.
(See figure on previous page.)
Fig. 4 Simvastatin treatment does not influence muscle regeneration in gastrocnemius muscle of mdx mice. A, B Quantification of muscle fiber
size based on laminin staining (not shown); n=5–6/group; mean ± SEM. C The quantitative analysis and representative photos of centrally
nucleated fibers (CNF) performed based on H&E staining showing a drop in CNF number in mdx animals treated with simvastatin when
compared to the vehicle group; scale bar: 100 μm; n=5–6/group; mean ± SEM. D Expression of myosin heavy chain isoform-coding gene: Myh3,
presented as mean ± SEM; n=10–13; qRT-PCR. E The protein level of FGF2 in the gastrocnemius muscle of dystrophic animals upon simvastatin
treatment; n=10–13/group; presented as mean ± SEM; ELISA. F myomiRs: miR-1, miR-133a-3p, and miR-206 expression upon simvastatin
treatment in gastrocnemius muscle of mdx animals presented as mean ± SEM; n=12–14; WT level marked with the dotted line; LNA qRT-PCR. G
The quantitative analysis and representative photos of Pax7-positive satellite cells in the gastrocnemius muscle; scale bar: 100 μm; n=9–12/group;
mean ± SEM; *for mdx simvastatin vs. mdx vehicle and $for mdx vehicle vs. WT comparison; *p < 0.05, ***p < 0.001, ****p < 0.0001, $$$p < 0.001,
$$$$p < 0.0001
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In contrast to the results obtained by Whitehead et al.,
which showed visibly reduced inflammatory cell infiltra-
tion [12], we did not observe the anti-inflammatory po-
tential of simvastatin. Moreover, the expression of the
Hmox1 gene, coding anti-oxidant, and cytoprotective
HO-1 enzyme was also not affected by the treatment.
Similar results were obtained by Verhaart et al. [15],
who reported no effect on inflammation even with the
prolonged by 2 months, in comparison to us, time of
drug administration. Furthermore, in opposition to the
published data suggesting the anti-fibrotic role of simva-
statin in mdx animals [12, 13], we did not observe any
effect of the treatment on fibrosis, neither in histological
assessment of collagen deposition nor expression of
fibrosis-related genes. Those observations were con-






























































































Fig. 5 Simvastatin treatment does not influence the angiogenic markers in the gastrocnemius muscle in dystrophic animals. A Decreased mRNA
level of angiogenesis-related genes Vegfa, Kdr, and Cxcl12 in the gastrocnemius muscle of vehicle-treated mdx mice and no changes in Ang1; n=
11–15/group; presented as mean ± SEM; WT level marked with the dotted line; qRT-PCR. The unaffected protein level of B VEGF, C SDF-1, and D
CD105 in the gastrocnemius muscle of statin-receiving animals; n=9–13/group; presented as mean ± SEM, ELISA. E The quantitative analysis and
representative photos of the blood vessels performed based on CD31/α-SMA double staining showing no difference in the gastrocnemius
muscle of mdx animals treated with simvastatin when compared to the vehicle group; n=5–6/group; presented as mean ± SEM; scale bar: 100
μm; *p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001
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described biomarker of DMD associated with regener-
ation, inflammation, and fibrosis [49, 50], which was also
not changed by simvastatin.
When gastrocnemius muscle was investigated, we no-
ticed a significant increase in the mean myofiber size
and a decline in the number of CNF. However, no alter-
ations were noticed in other regeneration-related param-
eters, such as the expression of Myh3 gene, FGF2
protein, muscle-specific myomiRs (miR-1, miR-133a-3p,
and miR-206), or the number of Pax7-positive satellite
cells. Similarly, no effect of simvastatin on dystrophic
muscle regeneration was demonstrated by Whitehead
et al. and Verhaart et al. [12, 15].
More importantly, in our study, simvastatin treatment
influenced neither the exercise capacity and forelimb
grip strength of the animals nor the muscle contractility
properties. Interestingly, when a measurement of the
specific force of the muscle was performed by White-
head et al. [12] and Verhaart et al. [15], they showed a
significant improvement and lack of any effect,
respectively.
To expand the already described knowledge, we de-
cided to investigate the modulation of angiogenesis, an-
other aspect of DMD progression. The improvement of
endothelial function and vasculoprotective action are
well-recognized statin effects [28, 51]. Importantly, our
previous studies revealed angiogenesis alterations in mdx
mice [4, 5, 31] which might be also age-dependent [40].
Similarly, in the present work, a significant drop in the
expression of angiogenic genes in the gastrocnemius
muscle was found on the mRNA and protein level but
without any impact of simvastatin treatment. Corres-
pondingly, no changes in the abundance of CD31/α-
SMA double-positive blood vessels were observed. Des-
pite the elevated number of the vessels in the diaphragm,
no other investigated factors were affected, suggesting
no profound effect on angiogenesis as the result of sim-
vastatin administration. Noteworthy, it shows that sim-
vastatin might not be influencing various muscles in the
same manner.
In summary, our study, in accordance with work by
Verhaart et al. [15] and Finkler et al. [16], did not sup-
port the hypothesis about the positive effect of statins in
DMD. The discrepant findings found by, e.g., Whitehead
et al. [12] might be related to several divergences in the
applied methodology, including age and genetic back-
ground of the mice, type and dose of the statin that was
used, route of administration, and length of time the
drug was given to the animals. Nevertheless, diverse
strategies give an undoubtful chance to investigate the
effects of statins from different perspectives and various
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Fig. 6 Simvastatin and simvastatin active metabolite concentration declines rapidly after administration. Simvastatin level measured in A plasma
and C diaphragm. Simvastatin acid analyzed in B plasma, D diaphragm, and E gastrocnemius after 30 min, 1 h, 2 h, and 4 h, and 24 h after the
last dose of the drug administration; n=4–5; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
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simvastatin was 10 mg/kg/d. In that matter, the ap-
plied approach was similar to the one used by other
groups [12, 15]. Moreover, despite the most promis-
ing results obtained by Whitehead et al. when simva-
statin was provided in food and water [12], we
strongly believe that oral gavage administration is
more relevant, taking into account a short half-life of
simvastatin in the circulation. What is more, this
route of delivery gives the opportunity to more pre-
cisely control the given dose. Importantly, our phar-
macokinetic experiment showed the detectable level
of the active metabolite, simvastatin acid, in the
plasma and tested muscles, with the highest concen-
tration obtained in the diaphragm. Noteworthy, due
to rapid decline in the concentration over time, we
cannot exclude the possibility that a higher amount
of the drug is required for the beneficial outcome of
the treatment, and as measured by us, the level is
much lower than reported by Whitehead et al. [12],
where administration of simvastatin at the same dose
in the food resulted in plasma levels of 170 ng/mL.
On the other hand, our data are more comparable to
Verhaart et al. results [15], although it is not clearly
stated whether the level of statin or its metabolite
was measured in that study. The lack of protective ef-
fect of simvastatin may be related to the relatively
short duration of the treatment. However, we even
observed a significant increase in the percentage of
necrotic fibers after a month-long experiment that
does not fully support conducting longer administra-
tion of simvastatin. Of note, an extension to 12 weeks
in Verhaart et al. study did not increase the plasma
simvastatin level and resulted in no improvement
[15]. Furthermore, it has to be emphasized that mice
used by Whitehead et al. and Verhaart et al. were
maintained on a C57BL/6J genetic background [12,
15], whereas in our study, we utilized mice bred on
C57BL/10ScSn and C57BL/6×FVB mixed background.
This was due to our previous and ongoing studies re-
garding various modulators of DMD progression, ori-
ginally initiated by investigation of the role of HO-1
in dystrophic mice by crossing HO-1-deficient ani-
mals (C57BL/6×FVB background) with mdx mice
(C57BL/10ScSn background) [9]. Importantly, our re-
sults are in line with Verhaart et al. study, indicating
that the lack of simvastatin effect is background-
independent.
Nonetheless, discrepancies in the performed experi-
ments should be carefully considered in future studies.
Conclusion
In conclusion, we demonstrated that simvastatin does
not significantly influence DMD pathology in mdx mice.
Our results do not support the hypothesis that statins
are a potential therapeutic option in DMD.
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Additional file 1: Supplementary Figure 1. Simvastatin treatment
does not change inflammation and fibrosis in the diaphragm of
mdx mice. (A) Representative pictures of hematoxylin and eosin (H&E)
staining with semi-quantitative analysis of inflammation; scale bar: 100
μm; mean ± SEM; n=4-6/group. (B) Unaffected by simvastatin treatment
expression of Hmox1 gene, presented as a mean ± SEM; n=10-13, qRT-
PCR. (C) Representative photos of Masson’s trichrome staining with semi-
quantitative analysis of collagen deposition showing no alterations in the
extent of fibrosis of simvastatin-treated animals; scale bar: 100 μm; n=5-6/
group. (D) Unaffected by simvastatin treatment expression of Spp1 gene,
presented as a mean ± SEM; n=10-13; qRT-PCR (E). Unchanged by the
treatment expression of fibrotic markers: Tgfb1, Mmp11, and Col1a1
mRNA; n=12-13/group, WT level marked with the dotted line; qRT-PCR.
Data are presented as mean ± SEM. No changes in diaphragm (F) cross-
sectional area (CSA) (G), muscle fiber size, and (H) percentage of CNF
were observed in statin-treated mdx mice; n=5-6; presented as mean ±
SEM; * for mdx simvastatin vs. mdx vehicle and $ for mdx vehicle vs. WT
comparison; *p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001, $ p <
0.05, $$$ p < 0.001, $$$$ p < 0.0001. Supplementary Figure 2. Simvastatin
treatment has no impact on angiogenic markers in the diaphragm
muscle of mdx mice. (A) Decreased mRNA level of angiogenesis-related
Vegfa in diaphragm muscle of vehicle-treated mdx mice and no changes
in Kdr, Ang1, and Cxcl12; n=12-13/group; presented as mean ± SEM; WT
level marked with the dotted line; qRT-PCR. The unaffected protein level
of (B) VEGF, (C) SDF-1, and (D) CD105 in diaphragm muscle of statin-
receiving animals; n=5-6/group; presented as mean ± SEM, ELISA. (E) The
quantitative analysis and representative photos of blood vessels per-
formed based on CD31/α-SMA double staining showing a significant ex-
acerbation in diaphragm muscle of mdx animals treated with simvastatin
when compared to the vehicle group; n=5-6/group; presented as mean
± SEM; scale bar: 100 μm; * p < 0.05, ***p < 0.001, ****p < 0.0001. Supple-
mentary Figure 3. Simvastatin does not affect Vegfa mRNA in mur-
ine myoblasts. Expression of Vegfa in C2C12 cell line after simvastatin
treatment, n=6/group, presented as mean ± SEM.
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